Literature DB >> 10426552

Investigations of the mechanism of the reduction of plasma glucose by cold-stress in streptozotocin-induced diabetic rats.

I M Liu1, C S Niu, T C Chi, D H Kuo, J T Cheng.   

Abstract

Exposure to a cold environment may increase the activity of the sympathetic nervous system inducing an elevation of plasma norepinephrine and may result in hyperglycemia. In the present study, we found that a hypoglycemic effect was produced in streptozotocin-induced diabetic rats after cold-exposure at 4 degrees C for 1 h. In addition to the blockade of this hypoglycemic effect by guanethidine (a ganglion-blocking agent) and prazosin (an alpha1-adrenoceptor antagonist), an increase of plasma norepinephrine was also observed in streptozotocin-induced diabetic rats receiving this cold-stress. Participation of sympathetic hyperactivity can thus be considered. Furthermore, naloxone, in a dose (0.5 mg/kg, i.p.) sufficient to block opioid receptors, reversed this hypoglycemia. Also, an increase of plasma beta-endorphin-like immunoreactivity was observed in streptozotocin-induced diabetic rats receiving this cold-stress. Intravenous injection of beta-endorphin into streptozotocin-induced diabetic rats produced a lowering of plasma glucose. Administration of methoxamine at a dose sufficient to activate the alpha1-adrenoceptors produced hypoglycemia and a similar increase of plasma beta-endorphin-like immunoreactivity in streptozotocin-induced diabetic rats. However, plasma beta-endorphin-like immunoreactivity level was not modified by similar treatment with methoxamine or cold-stress in normoglycemic rats. Therefore, beta-endorphin appears to be responsible for the induction of hypoglycemic effects in streptozotocin-induced diabetic rats after cold exposure which is different to the response in normal rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426552     DOI: 10.1016/s0306-4522(99)00068-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Transcranial electrostimulation activates reparative regeneration and the insulin-producing function of pancreatic B-cells in alloxan diabetes in rats.

Authors:  V P Lebedev; S V Bilichenko; N E Ordyan; S G Pivina; S P Nechiporenko; A A Puzyrev; E A Mikheeva; K K Kubacheva
Journal:  Neurosci Behav Physiol       Date:  2007-05

2.  Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats.

Authors:  S-L Hwang; I-M Liu; T-F Tzeng; J-T Cheng
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

3.  Cold exposure induces tissue-specific modulation of the insulin-signalling pathway in Rattus norvegicus.

Authors:  Alessandra L Gasparetti; Cláudio T de Souza; Márcio Pereira-da-Silva; Rachel L G S Oliveira; Mário J A Saad; Everardo M Carneiro; Lício A Velloso
Journal:  J Physiol       Date:  2003-08-01       Impact factor: 5.182

4.  Tramadol and hypoglycaemia: comparison with other step 2 analgesic drugs.

Authors:  Cindy Bourne; Aurore Gouraud; Amélie Daveluy; Aurélie Grandvuillemin; Pascal Auriche; Jacques Descotes; Thierry Vial
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

5.  Ophiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse model.

Authors:  Chao-Wei Huang; Tzu-Wen Hong; Ying-Jing Wang; Ko-Chien Chen; Ju-Chun Pei; Tai-Yuan Chuang; Wen-Sung Lai; Sheng-Hong Tsai; Richard Chu; Wei-Cheng Chen; Lee-Yan Sheen; Satoru Takahashi; Shih-Torng Ding; Tang-Long Shen
Journal:  BMC Complement Altern Med       Date:  2016-08-24       Impact factor: 3.659

6.  Mediation of Endogenous β-Endorphin in the Plasma Glucose-Lowering Action of Herbal Products Observed in Type 1-Like Diabetic Rats.

Authors:  I M Liu; J T Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-19       Impact factor: 2.629

7.  Association of Tramadol and Hypoglycemia in Diabetic Asians.

Authors:  Shang-Yi Li; Hsin-Hung Chen; Cheng-Li Lin; Su-Yin Yeh; Chia-Hung Kao
Journal:  J Clin Med       Date:  2018-10-24       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.